Ann: Quarterly Appendix 4C and Activities Report, page-11

"As part of Dimerix’ active business development program, in October 2023, Dimerix entered into itsfirst licensing agreement for DMX-200 in FSGS with Advanz Pharma. Dimerix retains all rights toDMX-200 in all other territories, and the company continues to pursue and progress licensing opportunities with potential partners outside the licensed territories."

"In December 2023, Dimerix was made aware of the PARASOL working group.PARASOL is acollaborative international effort that aims to define the quantitative relationships between short-term changes in biomarkers (proteinuria and GFR) and long-term outcomes in order to further support the use of alternative proteinuria-based endpoints as a basis for accelerated and traditional approval.The PARASOL group will achieve this in 2024 by conducting a large-scale analysis of existing data from patients of all ages with FSGS who are participants in observational cohort studies, regional or national registries, or real-world data sets. The project is sponsored by NephCure, the International Society ofGlomerular Disease, the Kidney Health Initiative, the National Kidney Foundation. The data analysis isled by a team from the Michigan Kidney Translational Medicine Center at the University ofMichigan. Dimerix intends on supporting this working group once industry has been invited to participate."